Literature DB >> 1374547

Levels of CD5+ B lymphocytes do not differ between patients with myasthenia gravis and healthy individuals.

Q Yi1, R Ahlberg, R Pirskanen, A K Lefvert.   

Abstract

CD5+ B cells might be involved in autoimmunity mainly as autoantibody-producing cells. To investigate the possible role of these cells in myasthenia gravis, we studied the numbers of CD5+ B cells, CD5- B cells, and CD19+ B cells as well as CD5+ T cells in the peripheral blood from 31 patients with myasthenia gravis and 31 healthy individuals. Both absolute percentages (percent of peripheral blood mononuclear cells) and relative percentages (percent of total CD19+ B cells) of CD5+ B cells were the same in patients as in controls. The numbers of CD5- B cells and CD19+ B cells were the same in both groups, whereas CD5+ T cells were lower in the patients. There was no correlation between clinical stage, sex, thymectomy, or pathology of thymus and the levels of CD5+ B cells, CD5- B cells, or CD19+ B cells. Patients treated with azathioprine had lower levels of CD5+ B cells than untreated patients and controls. Our results show that patients with myasthenia gravis have the same levels of CD5+ B cells as healthy individuals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374547     DOI: 10.1212/wnl.42.5.1081

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.

Authors:  C Ekerfelt; J Ernerudh; G Solders; M Vrethem
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

2.  Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients.

Authors:  F Heidenreich; T Jovin
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

3.  Pathological Findings in Myasthenia Gravis Patients with Thymic Hyperplasia and Thymoma.

Authors:  Ping Chen; Ying-Peng Wang; Dan-Lei Mou; Zheng-Yi Li; Qiu-Min Qu; Hong-Yan Wang; Yuan Deng; Xiao-Feng Li; Ting Wang; Xian-Hao Xu; Gang Zhao
Journal:  Pathol Oncol Res       Date:  2017-03-15       Impact factor: 3.201

4.  Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.

Authors:  JunMei Zhang; Ge Jia; Qun Liu; Jue Hu; Mei Yan; BaiFeng Yang; Huan Yang; WenBin Zhou; Jing Li
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.